Listed authentication company Dotz Nano (ASX:DTZ) has entered into a collaboration agreement for co-development, supply and licensing with Theracell Labs Ltd, a subsidiary of NASDAQ-listed biotech Orgenesis Inc.
Theracell Labs is a developer of cell and gene therapy devices, treatments and processing systems.
Under the agreement, Dotz’s end-to-end authentication technology will be used to mark disposable bioprocessing consumables, using on and in-product tagging techniques. Dotz’s non-toxic taggants will be embedded directly in these products during manufacturing without impacting the appearance or properties of the products. The agreement includes minimum purchase orders of US$5 million in the first year.
Speaking on the company’s agreement with a global biotech leader, Dotz Nano Chairman Bernie Brookes said, “This collaboration with a global biotech leader is testament to the innovation and versatility of our end-to-end authentication technology. Dotz’s variety of advanced materials and in-depth and extensive knowledge in the development of novel taggants and fluorescent materials allow us to offer advanced traceability solutions for bio-imaging applications that increase treatment precision and efficiency.”
As part of the licensing arrangements, Dotz and Theracell Labs will collaborate on the joint development of technology solutions to create an identification standard to tag patient-derived cells and facilitate real-time authentication of the patient’s cells. The joint development will extend to include the ability to trace therapeutic cells in-vitro to determine treatment efficacy.
If the collaboration agreement leads to the successful development of a commercialised product in the gene and cell-based therapy sector, Theracell Labs will be granted an exclusive, perpetual, global licence to manufacture, market, distribute and sell the results of the collaboration for the gene and cell-based therapy sector; and Theracell Labs will be required to pay Dotz 5% of net revenue from the sale of the product.